IL239234B - Compositions comprising anti-cd38 antibodies and lenalidomide - Google Patents

Compositions comprising anti-cd38 antibodies and lenalidomide

Info

Publication number
IL239234B
IL239234B IL239234A IL23923415A IL239234B IL 239234 B IL239234 B IL 239234B IL 239234 A IL239234 A IL 239234A IL 23923415 A IL23923415 A IL 23923415A IL 239234 B IL239234 B IL 239234B
Authority
IL
Israel
Prior art keywords
lenalidomide
antibodies
preparations containing
containing anti
preparations
Prior art date
Application number
IL239234A
Other languages
English (en)
Hebrew (he)
Other versions
IL239234A0 (en
Original Assignee
Sanofi Sa
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Univ California filed Critical Sanofi Sa
Publication of IL239234A0 publication Critical patent/IL239234A0/en
Publication of IL239234B publication Critical patent/IL239234B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL239234A 2012-12-07 2015-06-04 Compositions comprising anti-cd38 antibodies and lenalidomide IL239234B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (2)

Publication Number Publication Date
IL239234A0 IL239234A0 (en) 2015-07-30
IL239234B true IL239234B (en) 2021-05-31

Family

ID=50884019

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239234A IL239234B (en) 2012-12-07 2015-06-04 Compositions comprising anti-cd38 antibodies and lenalidomide
IL282542A IL282542A (en) 2012-12-07 2021-04-21 Compositions comprising anti-cd38 antibodies and lenalidomide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL282542A IL282542A (en) 2012-12-07 2021-04-21 Compositions comprising anti-cd38 antibodies and lenalidomide

Country Status (31)

Country Link
EP (2) EP3597191A1 (OSRAM)
JP (2) JP6499971B2 (OSRAM)
KR (2) KR20200143503A (OSRAM)
CN (1) CN105263520B (OSRAM)
AR (1) AR093844A1 (OSRAM)
AU (2) AU2013355064B2 (OSRAM)
BR (1) BR112015012987A2 (OSRAM)
CA (1) CA2893946A1 (OSRAM)
CL (2) CL2015001558A1 (OSRAM)
CY (2) CY1122478T1 (OSRAM)
DK (1) DK2928495T3 (OSRAM)
ES (1) ES2731548T3 (OSRAM)
HR (1) HRP20191034T1 (OSRAM)
HU (3) HUE044142T2 (OSRAM)
IL (2) IL239234B (OSRAM)
LT (2) LT2928495T (OSRAM)
LU (1) LUC00187I2 (OSRAM)
MX (2) MX366296B (OSRAM)
MY (1) MY191601A (OSRAM)
NL (1) NL301079I2 (OSRAM)
NZ (1) NZ709215A (OSRAM)
PH (1) PH12015501263A1 (OSRAM)
PL (1) PL2928495T3 (OSRAM)
PT (1) PT2928495T (OSRAM)
RS (1) RS58829B1 (OSRAM)
RU (1) RU2698911C2 (OSRAM)
SG (3) SG11201504315WA (OSRAM)
SI (1) SI2928495T1 (OSRAM)
TW (2) TW201919699A (OSRAM)
UA (1) UA118255C2 (OSRAM)
WO (1) WO2014089416A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP4516319A3 (en) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7585043B2 (ja) * 2018-04-13 2024-11-18 サムヤン ホールディングス コーポレイション レナリドミドを含む医薬組成物
KR102286498B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드의 경구용 코팅 정제 조성물
WO2019199132A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 다양한 용량의 레날리도마이드의 경구용 정제 조성물
JOP20200292A1 (ar) 2018-05-16 2020-11-15 Stichting Vumc Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
US11529339B2 (en) * 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
CN113574071B (zh) * 2019-03-15 2025-03-25 莫佛塞斯公司 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
TWI870415B (zh) * 2019-06-10 2025-01-21 日商武田藥品工業股份有限公司 使用抗cd38抗體之組合療法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
KR20220103969A (ko) * 2019-10-31 2022-07-25 모르포시스 아게 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
IL293563A (en) 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DE69800716T2 (de) 1997-04-14 2001-09-20 Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
BR112013006769B1 (pt) * 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
JP2016506388A (ja) 2016-03-03
CY1122478T1 (el) 2021-01-27
RU2698911C2 (ru) 2019-09-02
NZ709215A (en) 2020-08-28
KR20150091165A (ko) 2015-08-07
LUC00187I2 (OSRAM) 2024-07-01
CY2020040I2 (el) 2021-05-05
CL2018003292A1 (es) 2019-02-01
CA2893946A1 (en) 2014-06-12
WO2014089416A1 (en) 2014-06-12
SG10201704536PA (en) 2017-07-28
AU2013355064B2 (en) 2018-05-24
MY191601A (en) 2022-07-01
SG11201504315WA (en) 2015-07-30
RS58829B1 (sr) 2019-07-31
EP3597191A1 (en) 2020-01-22
HRP20191034T1 (hr) 2019-08-23
SI2928495T1 (sl) 2019-07-31
SG10201913783PA (en) 2020-03-30
EP2928495A4 (en) 2016-05-11
DK2928495T3 (da) 2019-06-24
TWI670062B (zh) 2019-09-01
AU2013355064A1 (en) 2015-07-09
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
PH12015501263A1 (en) 2015-08-17
MX2019008065A (es) 2019-09-23
CL2015001558A1 (es) 2015-10-02
PL2928495T3 (pl) 2019-09-30
KR102193045B1 (ko) 2020-12-18
BR112015012987A2 (pt) 2017-09-12
CN105263520B (zh) 2020-03-13
RU2015127089A (ru) 2017-01-13
HUS2000050I1 (hu) 2020-12-28
TW201919699A (zh) 2019-06-01
IL239234A0 (en) 2015-07-30
LTC2928495I2 (lt) 2024-11-25
HK1215536A1 (en) 2016-09-02
CY2020040I1 (el) 2021-03-12
LTPA2020537I1 (lt) 2020-12-28
JP2019070020A (ja) 2019-05-09
IL282542A (en) 2021-06-30
MX2015007189A (es) 2016-03-21
EP2928495B1 (en) 2019-03-27
LT2928495T (lt) 2019-07-10
JP6499971B2 (ja) 2019-04-10
HUE044142T2 (hu) 2019-09-30
MX366296B (es) 2019-07-04
AR093844A1 (es) 2015-06-24
PT2928495T (pt) 2019-07-04
ES2731548T3 (es) 2019-11-15
EP2928495A1 (en) 2015-10-14
HUS2000051I1 (hu) 2020-12-28
CN105263520A (zh) 2016-01-20
AU2018211258A1 (en) 2018-08-16
UA118255C2 (uk) 2018-12-26
KR20200143503A (ko) 2020-12-23

Similar Documents

Publication Publication Date Title
IL282542A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
CY2024011I2 (el) Αντισωματα anti-fcrn
IL286784A (en) Compositions of protein and antibody
IL272539B (en) Compositions and methods for immunotherapy
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
CL2015000027A1 (es) Anticuerpos e inmunoconjugados anti-cd22
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
IL230662A0 (en) Indazoles
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
EP2830660A4 (en) ANTI-SEMA4D ANTIBODIES AND EPITOPES
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
HUE045668T2 (hu) Oldat készítmények módosított anti-IL-23p19 antitestekbõl
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof
IL240514A0 (en) Pharmaceutical compositions containing dexketoprofen and tramadol
IL226913B (en) Composition comprising natural extracts

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed